HRP20141199T1 - Kombinacija od spoja glyt1 s antipsihoticima - Google Patents
Kombinacija od spoja glyt1 s antipsihoticima Download PDFInfo
- Publication number
- HRP20141199T1 HRP20141199T1 HRP20141199AT HRP20141199T HRP20141199T1 HR P20141199 T1 HRP20141199 T1 HR P20141199T1 HR P20141199A T HRP20141199A T HR P20141199AT HR P20141199 T HRP20141199 T HR P20141199T HR P20141199 T1 HRP20141199 T1 HR P20141199T1
- Authority
- HR
- Croatia
- Prior art keywords
- methanone
- piperazin
- methanesulfonyl
- trifluoro
- pyridin
- Prior art date
Links
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 229940005529 antipsychotics Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 claims 9
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 claims 9
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 9
- 239000002464 receptor antagonist Substances 0.000 claims 9
- 229940044551 receptor antagonist Drugs 0.000 claims 9
- 150000002367 halogens Chemical group 0.000 claims 8
- 229960005017 olanzapine Drugs 0.000 claims 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 6
- 229960001534 risperidone Drugs 0.000 claims 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 6
- -1 3-fluoro-5-trifluoromethyl-pyridin-2-yl Chemical group 0.000 claims 4
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229960004372 aripiprazole Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229960001057 paliperidone Drugs 0.000 claims 4
- 229960004431 quetiapine Drugs 0.000 claims 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- DJANLPFMLRNHFY-UHFFFAOYSA-N [4-(5-bromopyridin-2-yl)piperazin-1-yl]-[5-methylsulfonyl-2-(1,1,1-trifluoropropan-2-yloxy)phenyl]methanone Chemical compound FC(F)(F)C(C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2N=CC(Br)=CC=2)CC1 DJANLPFMLRNHFY-UHFFFAOYSA-N 0.000 claims 2
- UBTBYWQGFUUODC-UHFFFAOYSA-N [4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-(1,1,1-trifluoropropan-2-yloxy)phenyl]methanone Chemical compound FC(F)(F)C(C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)Cl)CC1 UBTBYWQGFUUODC-UHFFFAOYSA-N 0.000 claims 2
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 claims 2
- QMEGWSCLBODMOW-UHFFFAOYSA-N [5-methylsulfonyl-2-(1,1,1-trifluoropropan-2-yloxy)phenyl]-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound FC(F)(F)C(C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2N=CC(=CC=2)C(F)(F)F)CC1 QMEGWSCLBODMOW-UHFFFAOYSA-N 0.000 claims 2
- RUDPUJACTAVBBT-UHFFFAOYSA-N [5-methylsulfonyl-2-(1,1,1-trifluoropropan-2-yloxy)phenyl]-[4-[6-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound FC(F)(F)C(C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2N=C(C=CC=2)C(F)(F)F)CC1 RUDPUJACTAVBBT-UHFFFAOYSA-N 0.000 claims 2
- YUUGYIUSCYNSQR-UHFFFAOYSA-N bitopertin Chemical compound FC(F)(F)C(C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. Farmaceutska kombinacija, naznačena time, da obuhvaća netipičan antipsihotički lijek i antagonist receptora GlyT1 sljedeće formule I:
[image]
u kojoj
Ar je supstituirana 6-člana heteroaril-skupina koja sadrži jedan, dva ili tri atoma dušika, i pri čemu heteroaril-skupine mogu biti supstituirane s jednim ili više supstituenata odabranih iz skupine koju čine halogen, (C1-C6)-alkil ili (C1-C6)-alkil supstituiran s halogenom;
R1 je vodik ili (C1-C6)-alkil;
R2 je (C1-C6)-alkil supstituiran s halogenom;
R3, R4 i R6 su međusobno neovisno vodik, halogen (C1-C6)-alkil ili (C1-C6)-alkoksi;
R5 je SO2R10;
R10 je (C1-C6)-alkil opcijski supstituiran s halogenom;
i njihove farmaceutski prikladne kiselinske adicijske soli, kao i njihove enantiomerne oblike.
2. Farmaceutska kombinacija prema zahtjevu 1, naznačena time, da obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine risperidon, paliperidon, olanzapin, aripiprazol, kvetiapin ili ciprazidon te antagonist receptora GlyT1 odabran od sljedećih:
rac-[4-(3-kloro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
rac-[4-(5-bromo-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(6-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[5-metansulfonil-2-((S ili R)-2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[5-metansulfonil-2-((R ili S)-2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[4-((3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-((S)-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon ili
[4-((3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1,1-dimetil-etoksi)-fenil]-metanon.
3. Farmaceutska kombinacija prema zahtjevu 2, naznačena time, da obuhvaća netipičan antipsihotički lijek, odabran iz skupine koju čine risperidon, paliperidon, olanzapin, aripiprazol, kvetiapin ili ciprazidon te antagonist receptora GlyT1:
[4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon.
4. Farmaceutska kombinacija, naznačena time, da obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine olanzapin ili risperidon i antagonist receptora GlyT1 koji je sljedeći:
[image]
i njihove farmaceutski prikladne kiselinske adicijske soli, kao i njihove enantiomerne oblike.
5. Farmaceutska kombinacija prema zahtjevu 1, koja obuhvaća netipičan antipsihotički lijek i antagonist receptora GlyT1, naznačena time, da se upotrebljava u liječenju pozitivnih i negativnih simptoma kod shizofrenije.
6. Uporaba farmaceutske kombinacije koja obuhvaća netipičan antipsihotički lijek i antagonist receptora GlyT1 sljedeće formule:
[image]
u kojoj
Ar je supstituirana 6-člana heteroaril-skupina koja sadrži jedan, dva ili tri atoma dušika, i pri čemu heteroaril-skupine mogu biti supstituirane s jednim ili više supstituenata odabranih iz skupine koju čine halogen, (C1-C6)-alkil ili (C1-C6)-alkil supstituiran s halogenom;
R1 je vodik ili (C1-C6)-alkil;
R2 je (C1-C6)-alkil supstituiran s halogenom;
R3, R4 i R6 su međusobno neovisno vodik, halogen (C1-C6)-alkil ili (C1-C6)-alkoksi;
R5 je SO2R10;
R10 je (C1-C6)-alkil opcijski supstituiran s halogenom;
i njihove farmaceutski prikladne kiselinske adicijske soli, kao i njihove enantiomerne oblike, naznačena time, da je za proizvodnju lijeka za liječenje pozitivnih i negativnih simptoma kod shizofrenije.
7. Uporaba farmaceutske kombinacije prema zahtjevu 6, koja obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine risperidon, paliperidon, olanzapin, aripiprazol, kvetiapin ili ciprazidon te antagonist receptora GlyT1 odabran od sljedećih:
rac-[4-(3-kloro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
rac-[4-(5-bromo-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
rac-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(6-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[5-metansulfonil-2-((S ili R)-2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[5-metansulfonil-2-((R ili S)-2,2,2-trifluoro-1-metil-etoksi)-fenil]-[4-(5-trifluorometil-piridin-2-il)-piperazin-1-il]-metanon,
[4-((3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-((S)-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon ili
[4-((3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1,1-dimetil-etoksi)-fenil]-metanon,
naznačena time, da je za proizvodnju lijeka za liječenje pozitivnih i negativnih simptoma kod shizofrenije.
8. Uporaba farmaceutske kombinacije prema zahtjevu 7, koja obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine risperidon, paliperidon, olanzapin, aripiprazol, kvetiapin ili ciprazidon te sljedeći antagonist receptora GlyT1:
[4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il]-[5-metansulfonil-2-(2,2,2-trifluoro-1-metil-etoksi)-fenil]-metanon,
naznačena time, da je za proizvodnju lijeka za liječenje pozitivnih i negativnih simptoma kod shizofrenije.
9. Uporaba farmaceutske kombinacije prema zahtjevu 8, naznačena time, da se koristi kombinacija koja obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine olanzapin ili risperidon te antagonist receptora GlyT1 koji je sljedeći:
[image]
i njihove farmaceutski prikladne kiselinske adicijske soli, kao i njihove enantiomerne oblike.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10172316 | 2010-08-09 | ||
| PCT/EP2011/063533 WO2012019970A1 (en) | 2010-08-09 | 2011-08-05 | Combination of glyt1 compound with antipsychotics |
| EP11739097.1A EP2603219B1 (en) | 2010-08-09 | 2011-08-05 | Combination of glyt1 compound with antipsychotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141199T1 true HRP20141199T1 (hr) | 2015-02-13 |
Family
ID=44512856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141199AT HRP20141199T1 (hr) | 2010-08-09 | 2014-12-11 | Kombinacija od spoja glyt1 s antipsihoticima |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20120035156A1 (hr) |
| EP (1) | EP2603219B1 (hr) |
| JP (1) | JP2013533297A (hr) |
| KR (1) | KR101455947B1 (hr) |
| CN (1) | CN103068388A (hr) |
| AR (1) | AR084401A1 (hr) |
| AU (1) | AU2011288536B2 (hr) |
| BR (1) | BR112013003068A2 (hr) |
| CA (1) | CA2803656A1 (hr) |
| CL (1) | CL2013000378A1 (hr) |
| CR (1) | CR20130027A (hr) |
| CY (1) | CY1115886T1 (hr) |
| DK (1) | DK2603219T3 (hr) |
| EA (1) | EA201291477A1 (hr) |
| EC (1) | ECSP13012431A (hr) |
| ES (1) | ES2521596T3 (hr) |
| HR (1) | HRP20141199T1 (hr) |
| MA (1) | MA34457B1 (hr) |
| MX (1) | MX2013001166A (hr) |
| NZ (1) | NZ604891A (hr) |
| PE (1) | PE20131100A1 (hr) |
| PL (1) | PL2603219T3 (hr) |
| PT (1) | PT2603219E (hr) |
| SG (1) | SG187108A1 (hr) |
| SI (1) | SI2603219T1 (hr) |
| TW (1) | TW201211019A (hr) |
| WO (1) | WO2012019970A1 (hr) |
| ZA (1) | ZA201300434B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2848212C (en) | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| BR112015022174B1 (pt) | 2013-03-13 | 2022-07-05 | Sage Therapeutics, Inc | Compostos esteróides neuroativos, sua composição farmacêutica e seu uso |
| KR20160068975A (ko) * | 2013-12-03 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 약학 조성물 |
| IL248567B (en) * | 2014-04-30 | 2022-08-01 | Univ Nat Taiwan | Use of compounds known as d-amino acid oxidase inhibitors |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016057713A1 (en) * | 2014-10-07 | 2016-04-14 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| ES2884086T3 (es) | 2015-07-06 | 2021-12-10 | Sage Therapeutics Inc | Oxisteroles y sus procedimientos de uso |
| PE20180483A1 (es) | 2015-07-06 | 2018-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos |
| US10696712B2 (en) | 2015-07-06 | 2020-06-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| RS62222B1 (sr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda |
| AU2017337121B2 (en) | 2016-09-30 | 2022-01-27 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as NMDA modulators |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN110072874B (zh) | 2016-10-18 | 2022-08-12 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
| JP7355747B2 (ja) * | 2017-11-14 | 2023-10-03 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00116B (me) | 2003-08-11 | 2010-10-10 | Hoffmann La Roche | Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| CA2603939C (en) * | 2005-04-08 | 2013-08-27 | Pfizer Products Inc. | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors |
| GB0612420D0 (en) * | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| UA94615C2 (uk) * | 2006-06-28 | 2011-05-25 | Амген Інк. | Інгібітори транспортера-1 гліцину |
-
2011
- 2011-08-01 US US13/195,045 patent/US20120035156A1/en not_active Abandoned
- 2011-08-05 EP EP11739097.1A patent/EP2603219B1/en active Active
- 2011-08-05 SI SI201130310T patent/SI2603219T1/sl unknown
- 2011-08-05 SG SG2013003678A patent/SG187108A1/en unknown
- 2011-08-05 KR KR1020137005858A patent/KR101455947B1/ko not_active IP Right Cessation
- 2011-08-05 AR ARP110102840A patent/AR084401A1/es unknown
- 2011-08-05 PL PL11739097T patent/PL2603219T3/pl unknown
- 2011-08-05 WO PCT/EP2011/063533 patent/WO2012019970A1/en active Application Filing
- 2011-08-05 BR BR112013003068A patent/BR112013003068A2/pt not_active IP Right Cessation
- 2011-08-05 MX MX2013001166A patent/MX2013001166A/es not_active Application Discontinuation
- 2011-08-05 EA EA201291477A patent/EA201291477A1/ru unknown
- 2011-08-05 CN CN2011800387771A patent/CN103068388A/zh active Pending
- 2011-08-05 NZ NZ604891A patent/NZ604891A/en not_active IP Right Cessation
- 2011-08-05 PE PE2013000235A patent/PE20131100A1/es not_active Application Discontinuation
- 2011-08-05 AU AU2011288536A patent/AU2011288536B2/en not_active Ceased
- 2011-08-05 JP JP2013523575A patent/JP2013533297A/ja active Pending
- 2011-08-05 PT PT117390971T patent/PT2603219E/pt unknown
- 2011-08-05 ES ES11739097.1T patent/ES2521596T3/es active Active
- 2011-08-05 DK DK11739097.1T patent/DK2603219T3/da active
- 2011-08-05 MA MA35645A patent/MA34457B1/fr unknown
- 2011-08-05 CA CA2803656A patent/CA2803656A1/en not_active Abandoned
- 2011-08-08 TW TW100128250A patent/TW201211019A/zh unknown
-
2013
- 2013-01-16 ZA ZA2013/00434A patent/ZA201300434B/en unknown
- 2013-01-22 CR CR20130027A patent/CR20130027A/es unknown
- 2013-02-07 EC ECSP13012431 patent/ECSP13012431A/es unknown
- 2013-02-07 CL CL2013000378A patent/CL2013000378A1/es unknown
-
2014
- 2014-11-14 CY CY20141100952T patent/CY1115886T1/el unknown
- 2014-12-11 HR HRP20141199AT patent/HRP20141199T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130045379A (ko) | 2013-05-03 |
| PT2603219E (pt) | 2014-11-25 |
| CY1115886T1 (el) | 2017-01-25 |
| AU2011288536B2 (en) | 2014-10-09 |
| DK2603219T3 (da) | 2014-10-13 |
| KR101455947B1 (ko) | 2014-10-28 |
| WO2012019970A1 (en) | 2012-02-16 |
| NZ604891A (en) | 2015-01-30 |
| BR112013003068A2 (pt) | 2016-06-28 |
| MA34457B1 (fr) | 2013-08-01 |
| SG187108A1 (en) | 2013-02-28 |
| US20120035156A1 (en) | 2012-02-09 |
| EP2603219A1 (en) | 2013-06-19 |
| CA2803656A1 (en) | 2012-02-16 |
| ES2521596T3 (es) | 2014-11-13 |
| ZA201300434B (en) | 2013-09-25 |
| AU2011288536A1 (en) | 2013-01-31 |
| ECSP13012431A (es) | 2013-03-28 |
| CL2013000378A1 (es) | 2013-05-03 |
| CR20130027A (es) | 2013-03-04 |
| CN103068388A (zh) | 2013-04-24 |
| EA201291477A1 (ru) | 2013-06-28 |
| PL2603219T3 (pl) | 2015-03-31 |
| JP2013533297A (ja) | 2013-08-22 |
| MX2013001166A (es) | 2013-03-22 |
| SI2603219T1 (sl) | 2014-12-31 |
| TW201211019A (en) | 2012-03-16 |
| PE20131100A1 (es) | 2013-09-23 |
| EP2603219B1 (en) | 2014-09-17 |
| AR084401A1 (es) | 2013-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141199T1 (hr) | Kombinacija od spoja glyt1 s antipsihoticima | |
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| TW200740789A (en) | Pyridine and pyrimidine derivatives as mGluR2 antagonists | |
| HRP20151435T1 (hr) | Diamino heterociklički karboksamidni spoj | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
| WO2009013211A3 (en) | New pyrazol derivatives | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| MD4490C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| NZ601267A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| UA103478C2 (ru) | Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| WO2008155572A3 (en) | Fused quinoline derivatives useful as gaba modulators | |
| HRP20141108T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
| NO20085121L (no) | Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme | |
| HRP20130846T1 (hr) | Derivati indolizina i njihova uporaba u medicinske svrhe | |
| NO20090979L (no) | (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater | |
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines | |
| JO2676B1 (en) | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines | |
| GEP201706778B (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| WO2007025880A3 (en) | Pyrazolone derivatives as 11-beta hsd1 inhibitors | |
| BRPI0810402A2 (pt) | Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3 | |
| MX2009010505A (es) | Derivados de piridina y pirimidina como antagonistas de mglur2. | |
| MX2010001082A (es) | Composicion farmaceutica que contiene compuesto opticamente activo que tiene actividad agonista del receptor de trombopoyetina y compuesto intermedio para el mismo. |